Penicillin G Benzathine (Bicillin L-A) Injection Shortage: Latest Updates and Availability

What’s in Shortage

Penicillin G Benzathine Injection, commonly known by the brand name BICILLIN L-A, is currently in shortage. This medication is classified as an Anti-Infective and is administered as an injection. The shortage was first reported on April 26, 2023, and the status was last updated on February 12, 2026.

Which Manufacturers Are Affected

Pfizer Inc. is the manufacturer currently experiencing supply issues. The status of specific presentations is as follows:

• Bicillin L-A, Injection, 600,000 [iU]/1 mL (NDC 60793-700-10): Currently Unavailable. The manufacturer estimates recovery by December 2026.
• Bicillin L-A, Injection, 1,200,000 [iU]/2 mL (NDC 60793-701-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.
• Bicillin L-A, Injection, 2,400,000 [iU]/4 mL (NDC 60793-702-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.

For more information, Pfizer Inc. can be contacted at 844-646-4398.

Why There’s a Shortage

The manufacturer has cited manufacturing delays as the reason for the current shortage. The FDA database categorizes the reason as “Other.”

What Patients Should Do

If you or a loved one depends on this medication, please take the following steps:

• Consult Your Healthcare Provider: Discuss the shortage with your doctor to understand how it may affect your treatment plan.
• Speak with Your Pharmacist: Pharmacists often have the most current information regarding local stock and can help navigate supply issues.
• Contact the Manufacturer: You may reach out to Pfizer Inc. at 844-646-4398 for specific questions regarding their supply timeline.

Disclaimer: Patients should always consult their healthcare provider for medical advice and treatment options. Do not alter your prescribed treatment without professional medical guidance.

Source

Attribution: FDA Drug Shortage Database